

XX Congresso della Società GITMO

RIUNIONE NAZIONALE GITMO

ROMA, ERGIFE PALACE HOTEL, 7-8 MAGGIO 2026

Relazione del Presidente GITMO

Massimo Martino

Disclosures of Massimo Martino

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
Medac	x				x	x	
Kite/Gilead					x	x	
BMS					x	x	
Novartis					x	x	
Jansenn					x	x	
AMGEN					x	x	
JAZZ					x		
Takeda						x	
Therakos					x		
Vertex						x	
Pfizer					x	x	
Abbvie					x		
Roche					x	x	
Astellas					x	x	
Astra Zeneca					x	x	

THE NETWORK

	Tipologia Pazienti			Tipologia Trapianto	
Tipologia PT	Adulti	Pediatrici	Misti	Solo Autotrapianto	Auto + Allotrapianto
PTS (n=64)	54	8	2	20	44
PTC (n=11)	1	0	10	0	11
PTM (n=10)	7	0	3	2	8
Totali	62	8	15	22	63

Programmi Trapianto GITMO (n= 85)

Requisiti per il rinnovo accreditamento quantitativo GITMO-CNT

(Procedura Operativa Accreditemento GITMO-CNT AQ001 Rev.05)

	Accreditamento Auto	Accreditamento Allo
PTS	10 primi autotrapianti*/anno, per 2 anni <i>oppure</i> essere accreditati allo	10 primi allotrapianti**/anno, per 2 anni
PTC	10 primi autotrapianti*/Unità clinica Adulti/anno per 2 anni <i>oppure</i>	10 primi allotrapianti**/Unità clinica Adulti/anno per 2 anni <i>oppure</i>
PTM	5 primi autotrapianti*/Unità clinica Pediatrica/anno per 2 anni <i>oppure</i> essere accreditati allo	5 primi allotrapianti**/Unità clinica Pediatrica/anno per 2 anni

*primo autotrapianto: paziente mai trapiantato in passato, oppure sottoposto in precedenza ad allotrapianto, oppure già trapiantato presso altro PT

**primo allotrapianto: paziente mai trapiantato in passato, oppure sottoposto in precedenza ad autotrapianto, oppure già trapiantato presso altro PT

- **Tavolo Tecnico CNT e GITMO per problematica accreditamento Centri Pediatrici**
- Tempistiche (re)accreditemento CNT e JACIE: richiedere visita ispettiva almeno 6-9 mesi prima della scadenza




Numero soci: 1316

- Medici 533 (40.5%)
- Infermieri: 542(41.1%)
- Farmacisti: 7
- Biologi: 107
- Data manager e altre professioni non mediche: 54
- Soci under 40: 406 (30.9%)


Anno 2025: 139 nuovi soci

Autologous Transplants (n=95.068)



2023 vs 2025: -9.6%
2024 vs. 2025: -2.6 %

Autologous Transplants – Patient age at transplantation



Trapianti autologhi per fascia d'età — valori assoluti e % sul totale annuo

Fonte: GITMO, export 13/04/2026


Fascia	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
 <20	203 6.3%	180 5.8%	192 6.1%	216 6.3%	198 5.4%	211 5.9%	225 6.4%	206 5.8%	181 5.1%	196 6.0%	184 5.8%
 21-40	439 13.5%	388 12.5%	387 12.3%	379 11.0%	347 9.4%	368 10.3%	366 10.3%	388 10.9%	332 9.4%	294 9.0%	333 10.4%
 41-60	1439 44.4%	1383 44.6%	1353 42.9%	1519 44.2%	1649 44.7%	1551 43.4%	1504 42.5%	1510 42.4%	1472 41.5%	1328 40.4%	1292 40.5%
 >60	1098 33.9%	1086 35.0%	1142 36.2%	1230 35.8%	1383 37.4%	1342 37.6%	1333 37.7%	1350 37.9%	1449 40.8%	1371 41.7%	1298 40.7%
 ≥70	63 1.9%	65 2.1%	76 2.4%	96 2.8%	116 3.1%	99 2.8%	112 3.2%	106 3.0%	117 3.3%	95 2.9%	85 2.7%

Autologo - Riepilogo trend (2015 vs 2025)




Fascia	2015	2025	Δ assoluto	Δ %	Quota 2015	Quota 2025	Trend
■ <20	203	184	-19	-9%	6.3%	5.8%	Stabile
■ 21-40	439	333	-106	-24%	13.5%	10.4%	In calo
■ 41-60	1439	1292	-147	-10%	44.4%	40.5%	In calo lieve
■ >60	1098	1298	+200	+18%	33.9%	40.7%	In crescita
■ >70	63	85	+22	+35%	1.9%	2.7%	In crescita

Autologous Transplants (n. 3.107) - Indications 2025




Disease	%
MM	63
NHL	16
HD	9
ST	8
AML	1
AD	1
ALL	0,09

2025: Autologous Transplants (n. 3.107) – Source of HSC




N. of Transplants

Autologous transplants by disease



Autologous transplants in NHL




	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
NHL	773	790	779	789	765	768	811	696	725	556	496
Follicular	102	73	93	105	115	108	99	84	73	46	38
LBCL	347	366	381	349	353	360	368	269	295	200	190
Mantle	162	160	144	161	147	158	190	190	200	176	131
others	162	191	161	174	150	142	154	153	157	134	137

Autologo: variazione percentuale per tipo di linfoma tra il 2020 e il 2025

Tipo	2020	2025	Variazione
NHL (totale)	768	496	-35,4%
Follicolare (FL)	108	38	-64,8%
LBCL	360	190	-47,2%
Mantle (MCL)	158	131	-17,1%
Others	142	137	-3,5%


First and Second autologous transplant in Multiple Mieloma




GITMO DATA

Allogeneic Transplants

(n = 50.234)




2023 vs 2025: +7.3%
2024 vs. 2025: + 3.5 %



Disease	%
AML	44
ALL	14
MDS	9
NHL/HD	9
MPN	8

Allogeneic Transplants (n. 2152) - Indications 2025




Allogeneico: variazioni percentuali per patologia tra il 2024 e il 2025

Patologia	2024	2025	Variazione
AML	957	938	-2,0%
ALL	313	309	-1,3%
NHL/HD	200	199	-0,5%
MDS	183	209	+14,2%
MPN	132	171	+29,5%
MDS/MPN	57	66	+15,8%
CML	31	35	+12,9%
CLL	30	25	-16,7%
PCN	14	28	+100,0%

Allogeneic Transplants - Patient age at transplantation

N. of Transplants



Allogeneic Transplants

Anno	≤20	21-40	41-60	>60	≥70
2015	405 (23%)	366 (21%)	709 (40%)	253 (14%)	9 (1%)
2016	447 (24%)	312 (17%)	751 (41%)	296 (16%)	7 (0%)
2017	460 (23%)	350 (18%)	787 (40%)	357 (18%)	8 (0%)
2018	399 (20%)	322 (16%)	785 (39%)	398 (20%)	23 (1%)
2019	384 (19%)	326 (16%)	794 (40%)	442 (22%)	21 (1%)
2020	387 (20%)	311 (16%)	743 (38%)	480 (25%)	42 (2%)
2021	362 (18%)	269 (14%)	787 (40%)	489 (25%)	41 (2%)
2022	361 (18%)	280 (14%)	752 (38%)	540 (27%)	47 (2%)
2023	346 (17%)	289 (14%)	739 (36%)	631 (31%)	77 (4%)
2024	314 (15%)	272 (13%)	766 (37%)	731 (35%)	77 (4%)
2025	331 (16%)	290 (14%)	757 (37%)	775 (38%)	104 (5%)


Il dato più evidente è che nel 2025 la fascia **>60 anni supera per la prima volta le altre fasce**

Allogeneic Transplants


Fascia d'età	Trend	2015	2025	Δ assoluto	Δ %
≤ 20 anni	↘ calo	405 (23%)	331 (16%)	-74	-18%
21-40 anni	↘ calo	366 (21%)	290 (14%)	-76	-21%
41-60 anni	→ stabile	709 (40%)	757 (37%)	+48	+7%
> 60 anni	↗ forte crescita	253 (14%)	775 (38%)	+522	+206%
≥ 70 anni	↗↗ rapida crescita	9 (1%)	104 (5%)	+95	+1.056%
TOTALE				+515	+30%

Crescita del 30% in volume, ma il baricentro demografico si è spostato verso i pazienti anziani.


2025: Allogeneic Transplants (n. 2.152) – Donor Type




2025: Allogeneic Transplants (n. 2152) – Source of HSC





2025: Allogeneic Transplants (n. 2152) – Donor and Source of HSC



CAR-T procedures by year (n=2515)





2024 vs 2025: + 14%




Lymphoma

2025: CAR-T procedures by disease



2025 CAR-T procedures by Transplant Centre



> [Clin Lymphoma Myeloma Leuk.](#) 2026 Feb 24;S2152-2650(26)00056-X.
doi: 10.1016/j.clml.2026.02.009. Online ahead of print.

Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study

> [Am J Hematol.](#) 2026 Feb;101(2):350-355. doi: 10.1002/ajh.70145. Epub 2025 Nov 25.

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study

Differences between Physicians' and Nurses' Perspectives in Defining Core Nursing-Sensitive Outcomes in Adult HSCT and CAR-T Therapy: An Interdisciplinary Italian Delphi Consensus.

Cioce M, Sica S, Liptrott SJ, Lamberti F, Calza S, Cannici C, Diamanti O, Parisi A, Orlando L, Botti S, Nuzzo C, Vetrugno G, Laurenti P, Visintini C.

[Bone Marrow Transplant.](#) 2026 Mar;61(3):364-368. doi: 10.1038/s41409-025-02792-y. Epub 2025 Dec 27.

[Practice Guideline](#) > [Dig Liver Dis.](#) 2025 Dec;57(12):2257-2278.

doi: 10.1016/j.dld.2025.10.025. Epub 2025 Nov 10.

Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Società Italiana di Reumatologia (SIR), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Gastroenterologia (SIGE), Società Italiana di Malattie Infettive e Tropicali (SIMIT)

> [Am J Hematol.](#) 2025 Oct;100(10):1902-1905. doi: 10.1002/ajh.70030. Epub 2025 Aug 6.

Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS-Relapse Registry Study

Review > [Clin Transplant.](#) 2025 Aug;39(8):e70255. doi: 10.1111/ctr.70255.

Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell and in Solid Organ Transplantation: Updated Recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian Societies

> [Blood Transfus.](#) 2025 Nov-Dec;23(6):477-491. doi: 10.2450/BloodTransfus.986.

Exploring Italians' knowledge of, and perceptions and feelings about stem cell donation: a GITMO-IBMDR nationwide survey

> [Bone Marrow Transplant.](#) 2025 Oct;60(10):1406-1409. doi: 10.1038/s41409-025-02674-3. Epub 2025 Jul 26.

Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy

Observational Study > [BMJ Open Qual.](#) 2025 Jul 7;14(3):e003318. doi: 10.1136/bmjopen-2025-003318.

Perception of 'patient safety culture' among healthcare professionals in the field of haematopoietic stem cell transplantation and CAR-T therapy: a multicentre cross-sectional observational study by Italian Transplant Group for Bone Marrow Transplantation, Haematopoietic Stem Cells and Cell Therapy (GITMO)

> [Am J Hematol](#). 2025 Aug;100(8):1354-1364. doi: 10.1002/ajh.27731. Epub 2025 Jun 2.

Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the "Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare" (GITMO)

> [Leuk Lymphoma](#). 2025 Jun;66(6):1142-1145. doi: 10.1080/10428194.2025.2451723. Epub 2025 Jan 15.

Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey)

> [Blood Transfus](#). 2025 Mar;23(2):176-185. doi: 10.2450/BloodTransfus.790. Epub 2025 Jan 28.

Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT

> [Transplant Cell Ther](#). 2025 Jan;31(1):26.e1-26.e13. doi: 10.1016/j.jtct.2024.10.015. Epub 2024 Nov 4.

Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation



ECP e trapianto di cellule staminali allogeniche

Fad Sincrona | 26 giugno 2025



LA GvHD IN PEDIATRIA

Fad Sincrona | 8 ottobre 2025



ECP usage in early treatment lines and QoL impact

Fad Sincrona | 26 Novembre 2025



Convegno Educazionale GITMO

LE TERAPIE CELLULARI IN EMATOLOGIA TRA PASSATO, PRESENTE E FUTURO

Brescia

28-29 novembre 2025

Centro Paolo VI



GITMO 1000 miglia

Presente e futuro del ruolo
degli infermieri nelle
terapie cellulari

Reggio Emilia, Tecnopolo

16-17 gennaio 2026



Corso di Formazione GITMO

Trapianto e terapie cellulari:

cellule, donatori
e condizionamenti

Udine, 8-9 Ottobre 2026

Aula Polifunzionale Ospedale di Udine



GITMO
1000 **miglia**

g Mille Miglia
GITMO

IL TRAPIANTO E LE TERAPIE
CELLULARI: PRESENTE E FUTURO

CASTELFRANCO VENETO (TV)
Sala Convegni dell'Ospedale S. Giacomo Apostolo

19 OTTOBRE 2026

Premio *GITMO* 2026 alla Carriera







ASSOCIAZIONE ▾

AREA INFERMIERI

LIBRO GITMO E REPORT ANNUALI ▾

HANDBOOK GITMO

LINEE GUIDA

NEWS ▾

FORMAZIONE ▾

ISCRIZIONI ▾

OPPORTUNITA' DI LAVORO



Con il contributo non condizionante di



Ryder Cup – 03 ottobre 2025

**Circolo Golf Torino – La Mandria
Vs
Royal Park – I Roveri**

Euro 7.800 !!!!!



Cena di Beneficenza

**Il ricavato sarà devoluto al
GITMO**


Gruppo Italiano per il Trapianto Midollo Osseo,
Cellule Staminali Emopoietiche e Terapie Cellulari

06 | ORE
MAGGIO | 19:00

Villa Rosantica

Via Appia Antica, 288 - 00178 Roma

*L'ingresso prevede un'offerta
minima di partecipazione di €60*




Con il supporto di 
Roma



Bilancio 2025

utile di euro 88.149,38

Consiglio direttivo




- CONSIGLIO DIRETTIVO ALLARGATO



Francesca Bonifazi




Stefano Botti



Benedetto Bruno



Corrado Girmenia



Michele Malagola



Nicola Mordini




Francesca Patriarca




Simona Piemontese



Alessandra Picardi



Anna Maria Raiola



Grazie Elena Oldani!!!!!!!!!!!!!!!




Special Thanks To.....

Eliana Degrandi

Martina Pitea

Francesca Monari



ER Congressi

[Home](#)[Chi siamo](#)[Provider ECM](#)[Certificazione qualità](#)[La nostra formula](#)[Lavora con noi](#)[News](#)[Video gallery](#)[Congressi/Iscrizioni](#)[Contatti](#)

XXI Congresso della Società GITMO

RIUNIONE NAZIONALE GITMO

FIRENZE, PALAZZO DEI CONGRESSI, 3-4 MAGGIO 2027

